Diabetes
NEW TYPE 2 DIABETES WEIGHT LOSS STUDY – now enrolling
Intro: This Phase 3 clinical trial will study an experimental weight loss drug, eloralintide, which has helped some study participants lose up to 11.5% of their body weight at 12 weeks in an early-stage trial.
Investigational Drug: The drug is a long- acting form of the normal gluco-regulatory hormone amylin which has benefits similar to the GLP-1s in studies so far. The study drug might result in fewer side effects and provide an additional treatment option for patients.
To Qualify: Persons diagnosed with T2D for at least 6 months, with an A1C under 10%, on stable treatment with either diet/exercise alone or up to 3 orral meds for diabetes, aged 18 or over, not currently on insulin or other weight loss meds.
Goal: To assess the effect of the investigational medication on weight loss and A1C in persons with Type 2 Diabetes and overweight condition.
NEW TYPE 1 DIABETES WEIGHT LOSS STUDY – now screening
Intro: This study is designed to assist with safe, effective weight loss for persons with Type 1 Diabetes. This is a landmark trial as currently there are no GLP-1 type medications approved for weight loss in T1D.
Investigational Drug: The study drug is a single molecule that has both GLP-1 and GIP actions. It is a daily injectable designed to provide more flexibility, greater safety and fewer side effects for the population of T1D persons who could benefit medically from successful weight loss.
To Qualify: Persons with a documented diagnosis of T1D and who have been on uninterrupted insulin therapy for 1 year; a body mass index (BMI) greater than 23.0; an HbA1c of 7.0% to 10.0% confirmed by screening lab; able and willing to wear /use a CGM for the duration of the study.
Goal: To assess the effect of the investigational medication on weight loss and A1C in persons with Type 1 Diabetes and overweight condition.